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Introduction
Approximately 143,000 new cases and 52,000 deaths from colorectal cancer are expected in 2012 in the United States, a cancer morbidity and mortality that is second only to that of lung cancer (1) . Implementation of screening is considered an important factor in the decline of incidence and mortality from colorectal cancer over recent decades. However, the proportion of colorectal cancer deaths that can be prevented by screening is unclear with estimated mortality reductions ranging from approximately 20% to more than 50% (2) (3) (4) (5) . Among screening modalities, colonoscopy has yielded the largest mortality reductions. However, a limitation of colonoscopic screening is that it may be less effective for reducing risk (6) and mortality (7, 8) of right-sided than left-sided colorectal cancers. Incomplete compliance with guidelines, regardless of the modality, may also limit what can be achieved by screening alone; prevalence of colorectal cancer screening in U.S. adults combined, African Americans, Hispanics and uninsured individuals, respectively, was reported recently as 53.2%, 48.9%, 37.2% and 19.5% (9) . Thus, to optimize reductions in colorectal cancer incidence and mortality, additional effective interventions that are safe, easy to use and inexpensive are needed to complement screening.
Chemoprevention has been advocated as a potential adjunct to screening for reducing colorectal cancer morbidity and mortality (10). In randomized chemoprevention trials, calcium supplementation (11) and the non-steroidal anti-inflammatory drug (NSAID) aspirin (12, 13) were shown to reduce colorectal adenoma risk by 15-35%; aspirin yielded a greater 41% reduction in risk (12) for adenomas with advanced pathology, which are associated with a high risk of subsequent neoplasia (14) (15) (16) . Recently, in a meta-analysis of cardiovascular prevention trials, aspirin reduced colon cancer risk and mortality, respectively, by 24% and 35% (17) and colorectal cancer risk was reduced by 44% in Lynch syndrome patients receiving aspirin for a mean of 56 months (18).
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The anti-neoplastic actions of aspirin are attributed at least in part to inhibition of cyclooxygenase (COX) (19) but the level of gastrointestinal toxicity caused by aspirin and other NSAIDS (20) has restrained enthusiasm for their use as cancer preventive agents. Because inhibition of the COX-1 isoform is thought to be responsible for NSAID-related gastrointestinal toxicity, immense effort was directed to the development of selective COX-2 inhibitors (coxibs), such as celecoxib and rofecoxib, that would, hypothetically, conserve the beneficial effects of NSAIDs and minimize their toxicity. Although in randomized trials celecoxib and rofecoxib reduced colorectal adenoma risk by 24 -45% (14, 16, 21) , an associated increased risk of serious cardiovascular events with both agents prohibited the subsequent clinical use of coxibs for chemoprevention.
Selenium is an essential micronutrient with antioxidant activity and chemopreventive potential (22-24). It is incorporated into specialized selenocysteine-containing selenoproteins (25) that mediate redox-dependent and other cellular functions (24, 26, 27) . Evidence that selenium might help to prevent colorectal cancer came from the Nutritional Prevention of Cancer (NPC) Trial, a randomized controlled trial of selenium 200 µg daily as selenized yeast for the prevention of skin cancer (28). Although the intervention had no effect on the incidence of basal or squamous cell cancers, in planned secondary analyses there was a significant reduction of colorectal cancer incidence, which attenuated over time (29) . In a subsequent pooled analysis of data from three colorectal adenoma recurrence trials, participants' baseline blood selenium levels were inversely related to risk for developing metachronous (recurrent) colorectal adenomas (30). Selenium interventions were of significant benefit in four trials included in a Cochrane review of randomized controlled trials of antioxidant supplements administered for colorectal cancer prevention (31); there was some evidence that benefits of selenium were sustained in a later follow-up report (32) . While finding the methodologies of these four trials suboptimal, the Cochrane review authors considered the evidence for a Participants in a celecoxib and selenium adenoma trial 5 potential effect of selenium in preventing colorectal cancer sufficient to warrant randomized trials of this agent.
At the time the current study was designed, the majority of randomized trials for the chemoprevention of colorectal adenomas compared a single intervention to placebo. We hypothesized that combining relatively modest doses of two agents, each targeting a separate carcinogenesis pathway, would optimize efficacy while minimizing toxicity. The interventions we selected were celecoxib in a single daily dose of 400 mg and selenium as selenized yeast in a single daily dose of 200 µg. The 2x2 factorial design included each intervention alone, the combined interventions, and placebo. We report here the study design and baseline data of the complete trial cohort and an unavoidable modification to the study design-withdrawal of the celecoxib intervention-when the Federal Drug Administration terminated all coxib colorectal adenoma prevention trials because of unanticipated cardiotoxicity (33, 34). After the withdrawal of celecoxib, accrual to the trial was completed with randomization to selenium or placebo only.
In this report we focus on methodological adjustments that enabled us to complete trial accrual.
We believe that this experience may be helpful for the design of future cancer prevention trials and that dissemination of this experience need not be delayed until the trial results are reported after unblinding in late 2013.
Materials and Methods
Trial design. Originally, this was a phase III randomized, parallel, 2x2 factorial design trial of celecoxib (active versus placebo) crossed with a selenium supplement (active versus placebo) for prevention of metachronous (recurrent) colorectal adenomas ( Figure 1 ). The CONSORT 2010 guidelines for reporting randomized controlled trials (35) have been followed in the following description of completed accrual of the trial cohort. Participants in a celecoxib and selenium adenoma trial 6 with a diameter of 3 mm or more within the six months prior to registration were eligible.
Adenomas were categorized as non-advanced or advanced; the latter defined as adenomas with a diameter of 1+ cm, or any adenoma with villous features or high-grade dysplasia.
Patients with 1 or more advanced adenomas or ≥3 non-advanced adenomas were classified in a "high-risk adenoma" category. Patients with a family history of familial adenomatous polyposis or Lynch syndrome and those diagnosed with invasive cancer within the previous five years were among those excluded. Patients taking low-dose aspirin, defined as a maximum dose of 81 mg daily, were eligible. Participants in a celecoxib and selenium adenoma trial 7 plasma levels are measured at baseline and annually by atomic absorption spectrophotometry in all participants while on study.
Outcomes. The primary study outcome is colorectal adenoma recurrence. Recurrence rates are determined as the percentage of participants with metachronous adenomas diagnosed in each randomization group at surveillance colonoscopies, which are timed according to usual practice guidelines (37). The pre-specified primary outcome measures are recurrence rates with any (non-advanced or advanced) adenoma in participants taking celecoxib alone, selenium alone, celecoxib + selenium, or placebo. Additional planned analyses include the number, location and non-advanced/advanced/high-risk status of metachronous adenomas. A further pre-specified primary aim is to measure the type and incidence of adverse events occurring during prolonged treatment with celecoxib and selenium, given alone or in combination, with or without concomitant low-dose aspirin therapy in patients with colorectal adenomas. Participants in a celecoxib and selenium adenoma trial 8 those patients who were screened for possible eligibility gave written permission ("caregivers' consent") before their colonoscopy for: their records to be reviewed for this purpose by research staff after the procedure; and, if potentially eligible, for study staff then to contact them concerning possible participation in the study.
Patients who fulfilled all trial eligibility criteria were asked to provide written informed consent for participation, which included consent for isolation of their DNA to be used for analyses of sequence variations in selenoprotein genes. Those who consented to participate began a 4-week run-in assessment period of taking placebo medication for assessment of future compliance with taking study medication; they were blinded to the placebo nature of the run-in medication. The study intervention manager was notified of potential participants at the time a patient started run-in medication. Those who returned for clinic visits as scheduled and had taken at least 75% of the placebo medication doses were randomized into one of four groups, i.e. celecoxib + placebo, selenium + placebo, celecoxib + selenium, or double placebo hold. However, when informed that the celecoxib arm of the trial had already been permanently suspended by the EDSMC, the same day the FDA authorized uninterrupted continuation of the selenium arm of the trial. With the withdrawal of celecoxib, the study was modified to a randomized parallel two-group design, comparing selenium to placebo. Participants previously randomized to celecoxib with or without placebo were retained in the appropriate selenium or placebo arm ( Figure 2 ).
As noted, adenomas with advanced pathology are those at greatest risk for progression to colorectal cancer (38). It was apparent as accrual of the originally planned cohort of 1,600 individuals approached completion that 25-30% of randomized participants had one or more advanced adenomas at baseline. To enhance study power for demonstrating intervention effects in this higher risk subpopulation, recruitment of an additional 200 participants with one or more advanced adenomas was undertaken after recruitment of the original 1,600 participant cohort was completed. Because surveillance colonoscopy is indicated after three years in patients with an advanced adenoma rather than the five year interval for patients with non- (40). Based on the level of compliance in the WBF study, we assumed at least 90% compliance with obtaining the endpoint colonoscopy, resulting in a sample size of 360 per group. Our statistical power was 99% to detect a 25% reduction in the recurrence rate due to celecoxib and 95% to detect a 20% reduction in the recurrence rate due to selenium, assuming no negative interaction between celecoxib and selenium (two-sided 0.05 level of significance).
Even with a negative interaction of up to 20%, estimated power for detecting effects of celecoxib and selenium, respectively, was 96% and 78%.
Withdrawal of the celecoxib intervention did not alter the total sample size required. The statistical power was reassessed in light of data from our Ursodeoxycholic Acid (UDCA) colorectal adenoma prevention trial (41) . Forty two percent of participants had a recurrent adenoma during the three-year follow-up period of the UDCA trial; this implied an annual hazard of recurrence of 0.182. Based on results of other studies, we were interested in the power to detect a 25% reduction in adenoma recurrence rate due to selenium. Given new guidelines that patients with non-advanced adenomas should undergo colonoscopic surveillance after 5 rather than 3 years (37), we assumed an average follow-up of 4 years. This resulted in 94% statistical power to detect a 25% reduction due to selenium, based on a two-group test of proportions at a 2-sided 0.05 level of significance. 
Results from the UDCA trial (41) showed a 49% recurrence of non-advanced or advanced adenomas for those who had an advanced adenoma at baseline. The statistical power would have been 73% to detect a 33% reduction in the recurrence rate in those with advanced adenomas at baseline with the originally planned sample size. One hundred additional participants per group with one or more advanced adenomas were therefore added so that the statistical power increased to approximately 87%. This subset analysis was planned without regard to outcome data in the original 1,600 participants and so is not subject to the limitations of a data derived subset analysis.
Results and Discussion
Screening for eligibility and recruitment processes. Study coordinators attempted to contact a total of 20,436 patients who had recently undergone colonoscopic polypectomy for a preliminary assessment of potential study eligibility (Figure 3 Adverse event data from the 824 participants randomized to either celecoxib or placebo were contributed to a pooled analysis of adjudicated data for cardiovascular risk (the combination of cardiovascular death, myocardial infarction, stroke, heart failure, or thromboembolic event) in 7,950 participants from six placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis (42 
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(hazard ratio, 1.1; 95% CI, 0.6 to 2.0) for the 400-mg-daily dose of celecoxib, which was the dose used in our trial.
Participants in the Full Factorial Cohort continued active participation after the withdrawal of celecoxib, taking selenium or placebo, until their endpoint colonoscopy. Timing of the latter was not altered by termination of the trial's celecoxib arm. The effect of celecoxib on adenoma recurrence will be analyzed as originally planned, albeit with less statistical power than originally estimated. In secondary analyses, the length of time for which celecoxib was taken, the duration of any celecoxib effect after the intervention's termination, and modification of any selenium effects by celecoxib will be considered.
After withdrawal of celecoxib, a further 797 participants with non-advanced or advanced adenomas were randomized to selenium or placebo (Table 1, Participants in a celecoxib and selenium adenoma trial 13 Adenoma Cohorts, respectively, were 28.8, 34.5 and 39.6. Overall, an almost 60% majority of participants reported having ever smoked cigarettes.
Adenoma characteristics. Characteristics of participants' colorectal adenomas at baseline, including anatomic location, size and histological category, are shown in Table 2 .
Overall, 675 participants (37.9%) had one or more advanced adenomas and 366 (20.1%) had more than two adenomas. Adenomas from 202 of 203 participants in the Advanced Adenoma Cohort were ≥1 cm in size; the remaining participant qualified for the Advanced Adenoma Cohort by having an adenoma with villous histology. Of the 366 participants with more than two adenomas, 199 had at least one advanced adenoma and 164 did not. Thus, a total of 842 participants (47.2%) were in a high risk category by virtue of having one or two advanced adenomas (n=476) (37), or three or more non-advanced adenomas (n=167) (43), or three or more adenomas of which at least one was an advanced adenoma (n=199); the 167 participants with three or more non-advanced adenomas includes three in whom it is unknown whether the adenomas were advanced or non-advanced.
Concomitant low-dose aspirin. Approaching 50% of participants continued low-dose aspirin during the trial. As described, our sample size provides 94% statistical power to detect a 25% reduction due to the selenium intervention averaged across non-aspirin and low-dose aspirin users. As a secondary endpoint, we will also have adequate power to assess whether low-dose aspirin modifies the effect of selenium. The power calculation for the latter analysis assumes an adenoma recurrence rate of 49%, a marginal OR of 0.6 due to selenium (a 25% reduction in the recurrence rate), and a marginal OR for low-dose aspirin of 0.8 (a 10% reduction in the recurrence rate). We will have >80% power to detect an interaction odds ratio of ≤0.5 (a combined 33% reduction in the adenoma recurrence rate from selenium + low-dose aspirin). Causes for consideration of early termination. Results from two other selenium chemoprevention trials that were published during accrual to the current trial compelled us to consider early termination. The first was a report that supplementation with selenized yeast was associated with increased risk for type 2 diabetes (T2D) (46) and the second was the early termination, for lack of any effect, of the SELECT Trial of selenium and vitamin E for prostate cancer prevention (47).
In a secondary analysis of the NPC trial (28) that was published in 2007, a positive association was reported between selenium supplementation and self-reported diagnoses of T2D during the blinded phase of the trial (46). Participants were followed for an average of 7.7 years and the hazard ratio for development of T2D in those randomized to selenized yeast compared to placebo was 1.55 (95% CI, 1.03 to 2.33). Reports of diabetes came from three sources: self-report at clinic visits, reported use of drugs for diabetes, and reports in medical record documents. Medical record requests were then sent to the primary physicians for every patient with a report of diabetes.
In our ongoing selenium trial, fasting blood specimens for plasma glucose and other measurements are drawn from all participants at baseline and annually thereafter during the blinded phase of the trial. The EDSMC conducted an unblinded analysis of fasting plasma glucose data in our trial after the report of selenium-related increased risk for T2D in NPC trial participants; the investigators remained blinded. After this analysis, the Principal Investigator was instructed by the EDSMC to continue the trial without modification. The fasting blood specimens available for the complete trial cohort will provide a unique opportunity to compare the incidence of T2D in the selenium and placebo groups based on plasma glucose levels and other analyses that are planned. 
As noted, the SELECT Trial of the effects of selenium (200 µg daily as selenomethionine) and vitamin E (400 IU daily), alone or in combination, on the risk of prostate cancer in 35,533 men (48) was terminated in October, 2009 before completion. The reason for early termination was the result of a planned interim analysis by an independent data and safety monitoring committee. This showed that neither selenium nor vitamin E had any effect on prostate cancer incidence (47). In light of the early termination of SELECT, the EDSMC for our selenium trial requested a futility analysis in November, 2009. The committee recommended continuation of the trial without modification on the basis of the results of this analysis.
There are several important respects in which our ongoing selenium colorectal adenoma prevention trial differs from the SELECT trial and could, therefore, have a positive outcome.
First, selenium may have tissue-specific effects and the target organ for our trial is the colorectum, not the prostate. Second, the endpoint in our trial is adenoma recurrence as opposed to invasive cancer in SELECT, and it is possible that selenium may prevent or reverse premalignant earlier adenoma stages of colorectal carcinogenesis. Finally, selenized yeast, the intervention in our trial, contains additional selenium compounds (49) to selenomethionine and one or more of these compounds may have additional actions with chemopreventive potential to those of the selenomethionine-only intervention used in SELECT.
In summary, while accrual to our trial took longer than expected and administration of the celecoxib intervention was necessarily abbreviated, we are on schedule to unblind trial results for the full study cohort of 1,824 participants in 2013. Close involvement of a vigilant EDSMC enabled us to sustain the trial without compromising patient safety when first celecoxib was withdrawn and then the possibility that selenium supplementation may be associated with increased T2D risk arose. An interactive trial infrastructure involving study physicians, biostatisticians and other key investigators, EDSMC and the funding agency enabled us to enhance accrual of a high-risk group-patients with advanced adenomas-without delaying 
Participants in a celecoxib and selenium adenoma trial 17 completion of the trial. Most importantly, the study will answer in the setting of a randomized trial the previously unanswered question of whether a selenized yeast intervention prevents the development of premalignant colorectal adenomas. We will add to the existing body of information on coxib colorectal adenoma chemoprevention. Finally, we will provide detailed novel data of high public health significance on the potential adverse effects of selenium supplementation on glucoregulatory function and risk for T2D. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 4 25 participants marked more than one race, including 22 who selected a race they identified with primarily (and classified accordingly), and 3 who were unable to identify with one group (classified as Mixed). 5 Body Mass Index, calculated as 703*(weight in pounds)/(height in inches) 2 . 6 Ever smoker defined as 100 or more cigarettes. 7 History of colorectal polyp(s) on prior occasion to baseline colonoscopy with polypectomy that determined study eligibility 8 Family history of colorectal cancer in a first degree relative 9 Excluding non-melanoma skin cancer 10 Including basal cell, squamous cell, and skin cancer of unknown type 11 Number of years in total within the past twenty years taking aspirin or aspirin containing products at least twice a week for at least six consecutive months. 12 Number of years in total within the past twenty years taking a non-steroidal anti-inflammatory drug (NSAID), excluding aspirin, either over-the-counter or prescription at least twice a week for at least six consecutive months.
Cancer Research. 4 One participant was diagnosed with CRC less than 6 months after randomization. This is classified as a baseline event (i.e. not endpoint). 5 Advanced adenoma defined as having one or more of the following features: adenoma ≥1cm, with tubulovillous or villous histology, and/or with high grade dysplasia. 6 High risk defined as having an advanced adenoma or ≥3 adenomas. 4 Missing data in the original cohort because the first version of the form omitted this question. 5 Some participants refused to fill out the food frequency questionnaire. 6 Selenium sample not obtained due to blood draw difficulties 
